Dec 29, 2020
Alligator Bioscience recruits new Chief Medical Officer
Dec 04, 2020
Approved IND for Alligator Bioscience's CD40-targeting antibody mitazalimab
Nov 09, 2020
Alligator Bioscience presents at the SITC 35th Annual Meeting
Oct 27, 2020
Predicted therapeutic range dose levels reached in ATOR-1017 Phase I
Oct 22, 2020
Alligator Bioscience AB (publ): Interim report January-September 2020
Oct 22, 2020
Alligator Bioscience focuses on ATOR-1017 and mitazalimab
Sep 28, 2020
Alligator Bioscience appoints Gayle Mills as Chief Business Officer
Sep 24, 2020
Alligator Bioscience launches a new immuno-oncology concept
Sep 16, 2020
Alligator Bioscience receives patent approval for the drug candidate ATOR-1015
Sep 09, 2020
Alligator Bioscience presents an update regarding the Phase I study with the drug candidate ATOR-1015
Sep 04, 2020
Alligator Bioscience presents positive biomarker data demonstrating proof of mechanism in mitazalimab clinical Phase I study
Aug 27, 2020
Alligator Bioscience: Encouraging interim safety data in ATOR-1017 clinical Phase I study
Aug 25, 2020
Alligator Bioscience Virtual R&D Day - August 27, 2020
Jul 13, 2020
Alligator Bioscience AB (publ) Interim Report January-June 2020
Jun 10, 2020
Aptevo Therapeutics and Alligator Bioscience Present new Preclinical Data for ALG.APV-527 at the PEGS Virtual Interactive Global Summit
Jun 04, 2020
Alligator Bioscience and Scandion Oncology Sign Preclinical Agreement to Explore Combination Therapies for Chemotherapy and Immuno-oncology
Jun 01, 2020
Alligator Bioscience's Collaboration With Biotheus Inc. Proceeds and Second Payment is Received
Apr 07, 2020
Alligator Bioscience Increases Focus on Clinical Development
Apr 01, 2020
Alligator Bioscience Informs About Temporary Halt of Recruitment of New Patients due to the COVID-19 Pandemic
Mar 31, 2020
Notice of Annual General Meeting in Alligator Bioscience AB (publ)